TheProfitWatch

TARA - Protara Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
6.3 0.92 (14.52%) 0.0 (-0.07%) -0.02 (-0.21%) 0.0 (0.07%) 0.17 (2.7%) 0.75 (11.51%) 0.32 (4.95%) 0.01 (0.15%)

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.35
Diluted EPS:
-0.35
Basic P/E:
-20.6143
Diluted P/E:
-20.6143
RSI(14) 1m:
47.83
VWAP:
7.22
RVol:

Events

Period Kind Movement Occurred At

Related News